Safety study initiated with FG001
FluoGuide A/S ("FluoGuide") hereby announces that the first in vivo dosing of FG001 will commence today. This is an important milestone advancing FG001 for clinical evaluation in patients with glioblastoma. FluoGuide has chosen a strategic way forward in species selection with minimal risk.FluoGuide’s FG001 is designed to be well tolerated and its two main components have both demonstrated excellent tolerability profiles in humans. The result of the species qualification points FluoGuide to use the species with the longest delivery time and the first results from the clinical study with